CRISM developed the first national injectable opioid agonist treatment (iOAT) guideline in the world. This guideline includes two companion documents: a clinical guideline and an operational guidance document.
A synopsis of the Guideline was published in the Canadian Medical Association Journal
A podcast was also produced by CMAJ, which can be found at the link above.
You can also access the Guideline Development Methodology (as supplied by the authors) here
Supplemental Materials
- Supervised Consumption Sites vs iOAT | English | French
- Sample Program Expectations | English | French
- Sample Patient Bill of Rights | English | French
- Sample Client Safety Care Plan | English | French
- Sample Treatment Plan | English | French
- Sample Floor Plan | English | French
- Lessons Learned | English | French
- FAQ for Patients and Families | English | French
- Case Studies | English | French
- Sample Diacetylmorphine Titration Pre-Printed Order | English | French
- Sample Hydromorphone Titration Pre-Printed Order | English | French
- Sample Hydromorphone Titration Hospital Pre-Printed Order Package | English | French
- Sample Hydromorphone Maintenance Pre-Printed Order | English | French
- Journal Article: Perspectives of people with opioid use disorder on improving addiction treatments and services (Lachapelle, et al, 2020) | English
